SNU-449 Cells

Categories: Liver cancer cell lines Description: SNU-449 is a human hepatocellular carcinoma (HCC) cell line widely used in research to study liver cancer biology, drug resistance, apoptosis, and novel therapeutic strategies. As hepatocellular carcinoma is one of the most aggressive and common liver malignancies with poor prognosis, cell lines like SNU-449 are critical for understanding the molecular mechanisms underlying cancer progression and drug responses. SNU-449 has been particularly useful in studies involving apoptosis and ferroptosis, a regulated form of cell death associated with iron-dependent lipid peroxidation. For example, research has shown that agents like sorafenib, a standard treatment for advanced HCC, and artesunate synergize to induce ferroptosis in SNU-449 cells. This combination exacerbates lipid peroxidation and oxidative stress, leading to extensive cancer cell death. This synergy occurs because artesunate promotes lysosomal ferritin degradation (ferritinophagy), which increases free iron availability, while sorafenib impairs mitochondrial function and depletes glutathione, a critical antioxidant. SNU-449 has also been used to explore apoptotic pathways in liver cancer. For example, genistein, a natural isoflavone, induces apoptosis in SNU-449 cells by down-regulating thioredoxin-1 (Trx1), an antioxidant protein that regulates reactive oxygen species (ROS) and inhibits apoptosis. Genistein treatment increases ROS levels and activates apoptosis-related pathways, including caspase-3 activation and DNA fragmentation. These findings highlight SNU-449 as a valuable model for studying both apoptosis and ferroptosis, aiding in the development of targeted therapies for hepatocellular carcinoma. Organism: Human Tissue: Liver Disease: Adult hepatocellular carcinoma Synonyms: SNU449, NCI-SNU-449 Age: 52 years Gender: Male Ethnicity: Korean Morphology: Epithelial-like Growth Properties: Adherent Citation: SNU-449 (Cytion catalog number 305429) Biosafety Level: 1 Ncbi_ Taxid: 9606.0 Cellosaurus Accession: CVCL_0454 Viruses: Hepatitis B virus (HBV) DNA positive Mutational Profile: Mutation: ARID1A, p.Glu2250Argfs*28 (c.6747dupA), Mutation: AXIN1, p.Arg712Ter (c.2134C>T), homozygous, Mutation: TP53, p.Lys139Arg (c.416A>G), Mutation: TP53, p.Ala161Thr (c.481G>A), homozygous Culture Medium: RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) Supplements: Supplement the medium with 10% heat-inactivated FBS, add 2.5 g/L glucose and 25 mM HEPES Dissociation Reagent: Accutase Freeze Medium: As a cryopreservation medium, use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Thawing And Culturing Cells: Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks, for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes. Sterility: Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. Safety Precautions: When planning to store a cryovial in liquid nitrogen for future thawing, it is mandatory to adhere to stringent safety measures. Appropriate protective gloves and clothing are essential, and the use of a face mask or safety goggles is required during the transfer of frozen samples to or from the liquid nitrogen tank. This is to mitigate the risk of injury from potential cryovial explosions upon removal, which can result in the projection of sharp fragments. Warranty: We stand by the promise of delivering products with high cell viability and robust culture performance. To achieve the best results, please make sure you follow the storage and culture instructions detailed in the product information sheet closely. Your adherence to these guidelines is key to success. Subject To Material Transfer Agreements: If you intend to use Cytion cell lines solely for internal research at a single research site, please complete and sign our Material Transfer Agreement (MTA) and submit it along with your order.For any commercial applications - including but not limited to fee-for-service work, quality control testing, product release, diagnostic use, or regulatory studies - please complete the Intended Use Form so we can prepare a suitable agreement tailored to your project.Please note: The MTA applies only to certain cell lines. If this notice and the MTA document appear on a product page, the agreement is applicable. For cell lines not covered by the MTA, no reference to the agreement will be shown. The MTA is not valid for customers in the Americas, China, or Taiwan. Please contact our U.S. entity to receive the appropriate agreement. Required Product 1: 820700a Required Product 3: 860015.0 Required Product 4: 830100.0